Literature DB >> 28864715

Opposites attract in bispecific antibody engineering.

Marit J van Gils1, Rogier W Sanders2,3.   

Abstract

Bispecific antibodies show great promise as intrinsic combination therapies, but often suffer from poor physiochemical properties, many times related to poor heterodimerization. De Nardis et al. identify specific electrostatic interactions that facilitate efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties very similar to those of naturally occurring antibodies. This provides a new platform for the treatment of an array of diseases from cancer and autoimmune diseases to infectious diseases.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28864715      PMCID: PMC5582862          DOI: 10.1074/jbc.H117.793497

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Authors:  Kannan Gunasekaran; Martin Pentony; Min Shen; Logan Garrett; Carla Forte; Anne Woodward; Soo Bin Ng; Teresa Born; Marc Retter; Kathy Manchulenko; Heather Sweet; Ian N Foltz; Michael Wittekind; Wei Yan
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

2.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

3.  Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

Authors:  Charlotte F McDonagh; Alexandra Huhalov; Brian D Harms; Sharlene Adams; Violette Paragas; Shinji Oyama; Bo Zhang; Lia Luus; Ryan Overland; Stephanie Nguyen; Jinming Gu; Neeraj Kohli; Matt Wallace; Michael J Feldhaus; Arthur J Kudla; Birgit Schoeberl; Ulrik B Nielsen
Journal:  Mol Cancer Ther       Date:  2012-01-16       Impact factor: 6.261

4.  A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1.

Authors:  Camilla De Nardis; Linda J A Hendriks; Emilie Poirier; Tudor Arvinte; Piet Gros; Alexander B H Bakker; John de Kruif
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

5.  A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Authors:  Anna Z Wec; Elisabeth K Nyakatura; Andrew S Herbert; Katie A Howell; Frederick W Holtsberg; Russell R Bakken; Eva Mittler; John R Christin; Sergey Shulenin; Rohit K Jangra; Sushma Bharrhan; Ana I Kuehne; Zachary A Bornholdt; Andrew I Flyak; Erica Ollmann Saphire; James E Crowe; M Javad Aman; John M Dye; Jonathan R Lai; Kartik Chandran
Journal:  Science       Date:  2016-09-08       Impact factor: 47.728

Review 6.  Bispecific antibodies and their applications.

Authors:  Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal:  J Hematol Oncol       Date:  2015-12-21       Impact factor: 17.388

Review 7.  Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.

Authors:  Ji-Hee Ha; Jung-Eun Kim; Yong-Sung Kim
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

Review 8.  Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.

Authors:  Hongyan Liu; Abhishek Saxena; Sachdev S Sidhu; Donghui Wu
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

  8 in total
  1 in total

1.  Bispecific antibodies: a novel approach for targeting prominent biomarkers.

Authors:  Akshita Gupta; Yatender Kumar
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.